Address
18 Hasivim Street
Petah Tikva, 4959376
Israel
Phone
972 7 4719 5700
Website
Sector
Healthcare
Industry
Biotechnology
Employees
57
First IPO Date
June 26, 2020
| Name | Title | Pay | Year Born |
| Dalit Hazan | Deputy Chief Executive Officer and Executive Vice President of R&D, Clinical & Regulatory Affairs | 394,806 | 1972 |
| Dikla Czaczkes Akselbrad | Chief Executive Officer & Director | 558,344 | 1973 |
| Jonny Missulawin | Chief Financial Officer | 270,558 | 1987 |
| Ori Warshavsky | Chief Operating Officer - US | 418,497 | 1979 |
| Nurit Tweezer-Zaks | Chief Medical Officer | 0 | 1967 |
| Rivi Lev-ari | Vice President of Human Resource | 0 | N/A |
| Maria Rubin | Executive Vice President of Operations | 0 | N/A |
| Jean-Marc Hagai | Chief Commercial Officer | 0 | N/A |
| Tal Vilnai | General Counsel & Corporate Secretary | 0 | N/A |
PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.